Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma

References

• Zain JM, Hanona P. Aggressive T-cell lymphomas: 2021 updates on diagnosis, risk stratification and management. Am J Hematol. 2021;96(8):1027–1046. doi:10.1002/ajh.26270
   PubMed Web of Science ®Google Scholar
• Swerdlow SH. In world health organization classification: tumours of hematopoietic and lymphoid tissues. IARC. Blood. 2016 May 19; 127(20): 2375–2390
   Google Scholar
• Fiore D, Cappelli LV, Broccoli A, et al. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20(6):323–342. doi:10.1038/s41568-020-0247-0
   PubMed Web of Science ®Google Scholar
• Saleh K, Michot JM, Ribrag V. Updates in the treatment of peripheral T-cell lymphomas. J Exp Pharmacol. 2021;13:577–591. doi:10.2147/JEP.S262344
   PubMedGoogle Scholar
• Shah UA, Shah N, Qiao B, et al. Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States. Cancer. 2020;126(3):567–574. doi:10.1002/cncr.32556
   PubMed Web of Science ®Google Scholar
• Amengual JE, Raphael BG. Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2010;51(7):1347–1350. doi:10.3109/10428194.2010.486091
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Wilson WH. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2010;51(9):1583–1584. doi:10.3109/10428194.2010.508190
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–3100. doi:10.1182/blood-2013-12-542142
   PubMed Web of Science ®Google Scholar
• Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–240. doi:10.1016/S0140-6736(18)32984-2
   PubMed Web of Science ®Google Scholar
• Horwitz S, O'Connor OA, Pro B, et al. The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288–298. doi:10.1016/j.annonc.2021.12.002
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182–1189. doi:10.1200/JCO.2010.29.9024
   PubMed Web of Science ®Google Scholar
• O'Connor OA. Innovative approach to determine overall survival (OS) benefit for orphan diseases using case match control analyses (CMCA): the PROPEL experience of pralatrexate in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). J Clin Oncol. 2017;35(15_suppl):7521–7521. doi:10.1200/JCO.2017.35.15_suppl.7521
   Google Scholar
• Atallah-Yunes SA, Robertson MJ, Davé UP. Epigenetic aberrations and targets in peripheral T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22(9):659–665. doi:10.1016/j.clml.2022.04.015
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492–2499. doi:10.1200/JCO.2014.59.2782
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124(1):30–39. doi:10.1172/JCI69738
   PubMed Web of Science ®Google Scholar
• Chen IC, Sethy B, Liou JP. Recent update of HDAC inhibitors in lymphoma. Front Cell Dev Biol. 2020;8:576391. doi:10.3389/fcell.2020.576391
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhang M. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. Clin Epigenetics. 2020;12(1):169. doi:10.1186/s13148-020-00962-x
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–5834. doi:10.1182/blood-2010-10-312603
   PubMed Web of Science ®Google Scholar
• Iyer SP, Foss FF. Romidepsin for the treatment of peripheral T-cell lymphoma. Oncologist. 2015;20(9):1084–1091. doi:10.1634/theoncologist.2015-0043
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631–636. doi:10.1200/JCO.2011.37.4223
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7(1):11. doi:10.1186/1756-8722-7-11
   PubMed Web of Science ®Google Scholar
• Shimony S, Horowitz N, Ribakovsky E, et al. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: real-life data from a national multicenter observational study. Hematol Oncol. 2019;37(5):569–577. doi:10.1002/hon.2691
   PubMed Web of Science ®Google Scholar
• Bachy E, Camus V, Thieblemont C, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). J Clin Oncol. 2022;40(3):242–251. doi:10.1200/JCO.21.01815
   PubMed Web of Science ®Google Scholar
• Ma H, Davarifar A, Amengual JE. The future of combination therapies for peripheral T cell lymphoma (PTCL). Curr Hematol Malig Rep. 2018;13(1):13–24. doi:10.1007/s11899-018-0432-3
   PubMed Web of Science ®Google Scholar
• Ruan J, Zain J, Palmer B, et al. Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Adv. 2023;7(19):5771–5779. doi:10.1182/bloodadvances.2023009767
   PubMed Web of Science ®Google Scholar
• Jain S, Jirau-Serrano X, Zullo KM, et al. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Clin Cancer Res. 2015;21(9):2096–2106. doi:10.1158/1078-0432.CCR-14-2249
   PubMed Web of Science ®Google Scholar
• Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018;131(4):397–407. doi:10.1182/blood-2017-09-806737
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and sezary syndrome: a consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European Organisation for research and treatment of cancer. J Clin Oncol. 2011;29(18):2598–2607. doi:10.1200/JCO.2010.32.0630
   PubMed Web of Science ®Google Scholar
• Brammer J, Zinzani P, Zain J, et al. Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 primo trial: results of an interim analysis. Blood. 2021;138(Supplement 1):2456–2456. doi:10.1182/blood-2021-148939
   Google Scholar
• Horwitz SM, Moskowitz AJ, Mehta-Shah N, et al. The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: final results. Ann Oncol. 2022 Mar;33(3):288–298. doi:10.1002/hon.56_2879
   Google Scholar
• O'Connor OA, Falchi L, Lue JK, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019;134(17):1395–1405. doi:10.1182/blood.2019001285
   PubMed Web of Science ®Google Scholar
• Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137(16):2161–2170. doi:10.1182/blood.2020009004
   PubMed Web of Science ®Google Scholar
• Pombo De Oliveira MS, Loureiro P, Bittencourt A, et al. Geographic diversity of adult t-cell leukemia/lymphoma in Brazil. The Brazilian ATLL study group. Int J Cancer. 1999;83(3):291–298. doi:10.1002/(SICI)1097-0215(19991029)83:3<291::AID-IJC1>3.0.CO;2-P
   PubMed Web of Science ®Google Scholar
• Katsuya H, Ishitsuka K, Utsunomiya A, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570–2577. doi:10.1182/blood-2015-03-632489
   PubMed Web of Science ®Google Scholar
• Mehta-Shah N, Ratner L, Horwitz SM. Adult T-cell leukemia/lymphoma. J Oncol Pract. 2017;13(8):487–492. doi:10.1200/JOP.2017.021907
   PubMed Web of Science ®Google Scholar
• Cook L, Rowan A, Bangham C. Adult T-cell leukemia/lymphoma—pathobiology and implications for modern clinical management. Ann Lymphoma. 2021;5:29–29. doi:10.21037/aol-21-6
   Google Scholar
• Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the lymphoma study group (1984-87). Br J Haematol. 1991;79(3):428–437. doi:10.1111/j.1365-2141.1991.tb08051.x
   PubMed Web of Science ®Google Scholar
• Malpica L, Pimentel A, Reis IM, et al. Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. Blood Adv. 2018;2(6):607–620. doi:10.1182/bloodadvances.2017011106
   PubMed Web of Science ®Google Scholar
• Izutsu K, Makita S, Nosaka K, et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma. Blood. 2023;141(10):1159–1168. doi:10.1182/blood.2022016862
   PubMed Web of Science ®Google Scholar